Haritaki Terminalia chebula Retz.
Also called: myrobalan, black myrobalan
Haritaki (Terminalia chebula) is a tree native from the Indian subcontinent to western Yunnan and Indo-China, long used in Ayurveda, Unani, Tibb and Siddha medicine. Human trials have used extracts taken by mouth, mouth rinses and a skin cream.
- Category
- Botanical
- Part used
- Fruit (aqueous or ethanol extracts; mouth rinses and a cream in some trials)
- Strongest evidence
- C Limited
- Native range
- Native from the Indian subcontinent to China (western Yunnan) and Indo-China (POWO: "Indian Subcontinent to China (W. Yunnan) and Indo-China")
- Reviewed
- 2026-10-30
Class 1 Well studied in people. This entry cites 11 RCTs of Terminalia chebula alone: six oral, four mouth rinse and one topical cream; none tested Triphala or other formulas, and most were small. No systematic review stating a total count was found. [3]
Fact-checked 2026-10-30 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
CBrain, mood and sleep1 topic
CMouth and teeth1 topic
CHeart and blood vessels1 topic
CKidneys and bladder1 topic
CBlood sugar and weight1 topic
CSkin and hair1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Endothelial function in type 2 diabetes | C | A 12-week RCT in 60 patients found an aqueous extract (250 or 500 mg twice daily) improved endothelial function (reflection index) and other cardiovascular risk markers versus placebo. [2] |
| Knee joint discomfort with activity in overweight adults | C | An 84-day RCT in 105 overweight, otherwise healthy adults found a standardized aqueous fruit extract (250 or 500 mg twice daily) improved knee-joint scores (mKOOS global) versus placebo. [3] |
| Serum uric acid in hyperuricemia | C | In a 24-week, five-arm RCT (110 subjects), Terminalia chebula 500 mg twice daily lowered serum uric acid versus baseline and placebo; the effect was about half that of Terminalia bellerica 500 mg. [4] |
| Facial sebum, redness and wrinkles in healthy women | C | An 8-week placebo-controlled RCT of 250 mg capsules twice daily reported less forehead sebum in women with high baseline sebum, less cheek redness and lower facial wrinkle severity than placebo. [5] |
| Cognitive and negative symptoms in chronic schizophrenia | C | A 4-week double-blind RCT (six 500 mg capsules daily) reported improved cognitive-impairment scores, negative symptoms and excitement/activity versus placebo. [6] |
| Dental plaque and gingivitis (mouth rinse) | C | A 4-week RCT in 90 students found a Terminalia chebula mouthwash reduced plaque and gingival bleeding versus placebo, about as much as chlorhexidine 0.2%. [7] |
Main constituents: Chebulic acid, chebulinic acid and chebulagic acid named as major bioactive compounds; chebulagic acid and chebulanin linked to antioxidant activity [1]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- Aqueous extract 250 mg or 500 mg twice daily for 12 weeks (type 2 diabetes trial). [2]
- Six 500 mg capsules daily in two divided doses for 4 weeks (schizophrenia trial). [6]
- 10% mouth rinse twice daily for 2 weeks (gingivitis trial). [8]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)Nothing found
No published information found in the sources checked.
Details and sources - Pregnancy and breastfeedingNothing found
No published information found in the sources checked.
Details and sources - Interactions with medicinesNothing found
No published information found in the sources checked.
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notifications3 on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsNone found
No published information found in the sources checked.
Details and sources
- In an 84-day trial in 105 adults, all safety blood markers stayed within normal limits and no adverse events were reported. [3]
- No serious adverse effects were reported in a 4-week trial in people with schizophrenia. [6]
- All formulations in a 24-week hyperuricemia trial were well tolerated. [4]
- In a 12-week melasma trial, skin irritation was significantly less frequent with a 5% Terminalia chebula cream than with 2% hydroquinone. [9]
Identity, quality and standardization
- Studies have used different parts (fruits, seeds, galls, barks) extracted with different solvents (aqueous, ethanol, methanol, chloroform, ethyl acetate). [1]
Regulatory status
- US: under DSHEA, FDA does not have the authority to approve dietary supplements before they are marketed; firms are responsible for ensuring their products are not adulterated or misbranded. [10]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- Chebulic acid, chebulinic acid and chebulagic acid (named as major bioactive compounds); chebulanin Tannins (PubChem CID 442674 describes chebulagic acid as a tannin) [P1]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- FDA's published NDI notification list has 3 entries naming Terminalia chebula (earliest NDI 128 submitted 2001-11-09, a multi-ingredient product; most recent NDI 1389 submitted 2025-03-21, a purified Terminalia chebula extract). Each notification covers one firm's specific ingredient and conditions of use; the list does not state FDA's response. [P3]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
- No IARC or NTP carcinogenicity evaluation of haritaki (Terminalia chebula) was found (IARC Monographs list of classifications, Volumes 1–142, and NTP technical reports checked 2026-10-29). [P4]
- The NTP Technical Reports index (TR-001 to TR-606) lists no study of Terminalia or haritaki (checked 2026-10-29). [P5]
Liver (NIH LiverTox)
- No published information found in the sources checked.
Interactions with medicines
- No published information found in the sources checked.
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; a firm may petition FDA for an exemption under 111.75(a)(1)(ii). [P6]
Supply and conservation
- IUCN Red List: Least Concern (LC), via GBIF species API, retrieved 2026-10-29. [P7]
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- No published information found in the sources checked.
Pregnancy and breastfeeding
- No published information found in the sources checked.
Sources for this profile
- Hassan Bulbul MR, et al. A comprehensive review on the diverse pharmacological perspectives of Terminalia chebula Retz. Heliyon 2022;8(8):e10220 (PMID 36051270), 2022-08. pubmed.ncbi.nlm.nih.gov
- PubChem. Chebulagic acid, CID 442674: description (retrieved 2026-10-29), 2026-10-29. pubchem.ncbi.nlm.nih.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs. List of Classifications, Volumes 1–142 (retrieved 2026-10-29), 2026-10-29. monographs.iarc.who.int
- National Toxicology Program. Technical Reports (TR series index, TR-001 to TR-606; retrieved 2026-10-29), 2026-10-29. ntp.niehs.nih.gov
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
- GBIF species API: IUCN Red List category for Terminalia chebula Retz., 2026-10-29. api.gbif.org
Sources
- Hassan Bulbul MR, et al. A comprehensive review on the diverse pharmacological perspectives of Terminalia chebula Retz. Heliyon 2022;8(8):e10220 (PMID 36051270), 2022-08. pubmed.ncbi.nlm.nih.gov
- Pingali U, Sukumaran D, Nutalapati C. Effect of an aqueous extract of Terminalia chebula on endothelial dysfunction, systemic inflammation, and lipid profile in type 2 diabetes mellitus: a randomized double-blind, placebo-controlled clinical study. Phytother Res 2020;34(12):3226-3235 (PMID 32618037), 2020-12. pubmed.ncbi.nlm.nih.gov
- Lopez HL, et al. Effects of dietary supplementation with a standardized aqueous extract of Terminalia chebula fruit on joint mobility, comfort, and functional capacity in healthy overweight subjects: a randomized placebo-controlled clinical trial. BMC Complement Altern Med 2017;17(1):475 (PMID 28969626), 2017-10. pubmed.ncbi.nlm.nih.gov
- Usharani P, et al. A randomized, double-blind, placebo-, and positive-controlled clinical pilot study to evaluate the efficacy and tolerability of standardized aqueous extracts of Terminalia chebula and Terminalia bellerica in subjects with hyperuricemia. Clin Pharmacol 2016;8:51-59 (PMID 27382337), 2016-06. pubmed.ncbi.nlm.nih.gov
- Chakkalakal M, et al. Randomized double-blind placebo-controlled supplementation with standardized Terminalia chebula fruit extracts reduces facial sebum excretion, erythema, and wrinkle severity. J Clin Med 2023;12(4):1591 (PMID 36836126), 2023-02. pubmed.ncbi.nlm.nih.gov
- Banazadeh M, et al. Evaluating the effect of black myrobalan on cognitive, positive, and negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled trial. Phytother Res 2022;36(1):543-550 (PMID 34814232), 2022-01. pubmed.ncbi.nlm.nih.gov
- Gupta D, et al. Comparative evaluation of Terminalia chebula extract mouthwash and chlorhexidine mouthwash on plaque and gingival inflammation: 4-week randomised control trial. Oral Health Prev Dent 2015;13(1):5-12 (PMID 25386630), 2015. pubmed.ncbi.nlm.nih.gov
- Gupta D, et al. Effect of Terminalia chebula extract and chlorhexidine on salivary pH and periodontal health: 2 weeks randomized control trial. Phytother Res 2014;28(7):992-998 (PMID 24123617), 2014-07. pubmed.ncbi.nlm.nih.gov
- Kheirieh AE, et al. Evaluating the efficacy of Terminalia chebula Retz. 5% cream compared to hydroquinone 2% cream in the treatment of melasma. Avicenna J Phytomed 2024;14(5):527-536 (PMID 40255950), 2024-09. pubmed.ncbi.nlm.nih.gov
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (Content current as of 08/27/2026), 2026-08-27. fda.gov
- Pokuri VK, Kumar CU, Pingali U. A randomized, double-blind, placebo-controlled, cross-over study to evaluate analgesic activity of Terminalia chebula in healthy human volunteers using a mechanical pain model. J Anaesthesiol Clin Pharmacol 2016;32(3):329-332 (PMID 27625480), 2016-07. pubmed.ncbi.nlm.nih.gov
- Palit M, Hegde SK, Bhat SS. Effectiveness of mouthrinse formulated from aqueous extract of Terminalia chebula on salivary Streptococcus mutans count and pH among 8- to 12-year-old school children of Karnataka: a randomized clinical trial. Int J Clin Pediatr Dent 2016;9(4):349-354 (PMID 28127168), 2016-10. pubmed.ncbi.nlm.nih.gov
- Nayak SS, et al. Effectiveness of mouthrinse formulated from ethanol extract of Terminalia chebula fruit on salivary Streptococcus mutans among 12 to 15 year old school children of Belgaum city: a randomized field trial. J Indian Soc Pedod Prev Dent 2012;30(3):231-236 (PMID 23263427), 2012-07. pubmed.ncbi.nlm.nih.gov
- Plants of the World Online (POWO), Royal Botanic Gardens, Kew; WCVP data. Terminalia chebula Retz. (accessed 2026-10-29; native range: "Indian Subcontinent to China (W. Yunnan) and Indo-China"), 2026-10-29. powo.science.kew.org
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.